Feline Hepatic Lipidosis

Feline hepatic lipidosis (FHL) is the most common form of liver dysfunction in cats, characterized by the excessive accumulation of triglycerides and other lipids within hepatocytes, leading to potentially severe and life-threatening liver failure [3]. The condition arises when the rate of fatty acid influx into the liver—driven primarily by peripheral fat mobilization during periods of anorexia—overwhelms the liver's capacity for fatty acid oxidation and export via very-low-density lipoproteins (VLDL) [1]. FHL can occur either as a primary (idiopathic) condition or, more commonly, secondary to a wide range of underlying diseases that trigger prolonged inappetence [3]. While serious, the prognosis is good when the condition is recognized early and aggressive nutritional support is promptly initiated [3].

Primary (Idiopathic) vs. Secondary FHL

FHL is classified as either idiopathic, in which no underlying disease is identified despite thorough investigation, or secondary, in which a concurrent illness precipitates the anorexia that triggers lipid accumulation [3][8]. Secondary FHL is considerably more common; virtually any disease causing sustained anorexia can be a precipitating factor. Common concurrent conditions include pancreatitis, inflammatory bowel disease, cholangiohepatitis (the combination of which is termed "triaditis"), diabetes mellitus, neoplasia, renal disease, and urinary obstruction [4][5].

Pathophysiological Mechanisms

Cats possess unique metabolic characteristics that render them particularly susceptible to hepatic lipidosis compared to other species [7]. These include a constitutively high reliance on amino acids and fat as energy substrates, limited hepatic glucokinase activity, and an obligate need for dietary protein to maintain gluconeogenesis [2][5].

The central pathophysiological event is an imbalance between fat delivery to the liver and fat removal from it [1]:

1. ·

   Peripheral fat mobilization: During anorexia or negative energy balance, adipose tissue undergoes lipolysis driven by stress hormones (catecholamines, glucagon, cortisol), releasing non-esterified fatty acids (NEFAs) into the circulation. These NEFAs are transported to the liver in large quantities [1][2].

2. ·

   Hepatic triglyceride accumulation: Within hepatocytes, NEFAs are re-esterified into triglycerides (TAG). Normally, TAG would either undergo beta-oxidation for energy or be packaged into VLDL particles for export. In FHL, both pathways are impaired [1][2].

3. ·

   Impaired VLDL export: VLDL synthesis requires adequate apolipoprotein B and phospholipid availability. Protein malnutrition—a consequence of prolonged anorexia—reduces the supply of apolipoproteins necessary for VLDL assembly, trapping triglycerides within the hepatocyte [2][8].

4. ·

   Defective fatty acid oxidation: Carnitine is essential for the transport of long-chain fatty acids into mitochondria for beta-oxidation. Cats have limited capacity for endogenous carnitine synthesis, and prolonged anorexia leads to a relative carnitine deficiency, further impairing mitochondrial fatty acid oxidation [2][8].

5. ·

   Oxidative damage: Peroxisomal and mitochondrial dysfunction from oxidative stress further reduces the capacity for fatty acid disposal, compounding lipid accumulation [2].

6. ·

   Hepatocellular dysfunction and failure: As lipid accumulation increases, hepatocytes become distended with lipid vacuoles, impairing normal metabolic and excretory functions, causing cholestasis, elevations in liver enzymes, hyperbilirubinemia, and eventually hepatic failure if untreated [1][5].

Risk Factors

• ·Obesity: Obese cats have larger peripheral fat stores available for mobilization and may be more susceptible to rapid lipid influx [1][5]
• ·Middle-aged cats: Most commonly affects cats between 2 and 12 years of age, though any age can be affected [5]
• ·Prolonged anorexia: Even 2–7 days of complete anorexia may be sufficient to initiate FHL in susceptible individuals [3]
• ·Stress events: Changes in environment, new pets, owner absence, or dietary change can precipitate voluntary food refusal [3][5]

Diagnosis of FHL rests on a combination of history, physical examination, clinicopathologic findings, and diagnostic imaging, often confirmed by cytology or histopathology [1][3].

History and Physical Examination

A history of recent anorexia (days to weeks), prior obesity, and weight loss—combined with physical findings of jaundice, hepatomegaly, muscle wasting, and lethargy—is highly suggestive [1][5]. Identifying whether a concurrent underlying disease is present is critical, as it affects the therapeutic approach and prognosis [3].

Laboratory Findings

Serum Biochemistry:

• ·ALT (Alanine Aminotransferase): Typically markedly elevated, reflecting hepatocellular damage and lipid accumulation [1][5]
• ·ALP (Alkaline Phosphatase): Elevated, often disproportionately high relative to other liver enzymes; in cats, ALP elevation is considered more clinically significant than in dogs because feline ALP has a shorter half-life [1][7]
• ·TBIL (Total Bilirubin): Elevated, often markedly so, due to intrahepatic cholestasis caused by lipid-laden hepatocytes obstructing bile canaliculi [1][3]
• ·ALB (Albumin): Low to low-normal; hypoalbuminemia reflects reduced hepatic synthetic capacity and protein malnutrition [5]
• ·GLOB (Globulins): Variable; may be reduced due to poor nutritional state or elevated if concurrent inflammatory disease is present [5]
• ·BUN (Blood Urea Nitrogen): Often low, reflecting reduced hepatic urea cycle function and protein malnutrition; paradoxically may be elevated if concurrent renal disease is present [5][2]
• ·Glucose: May be low (hypoglycemia due to impaired gluconeogenesis) or high (if concurrent diabetes mellitus or stress hyperglycemia is present) [5]
• ·Electrolytes: Hypokalemia and hypophosphatemia are common, especially after refeeding begins; these can cause profound muscle weakness and hemolytic anemia [1][5]
• ·Cholesterol: May be elevated or reduced depending on disease stage [5]

Complete Blood Count (CBC):

• ·HCT (Hematocrit): Anemia is variably present; Heinz body hemolytic anemia may be identified on blood smear due to oxidative damage to erythrocytes [1][5]
• ·PLT (Platelets): Thrombocytopenia may be noted; coagulation abnormalities, including prolonged PT and aPTT, can develop [1]
• ·WBC (White Blood Cells): Leukocytosis may be present if concurrent infection or inflammation is identified; not a consistent finding in uncomplicated FHL [5]

Urinalysis:

• ·Bilirubinuria is frequently detected [1]
• ·Ammonium biurate crystalluria may be seen in severe cases with hepatic encephalopathy [5]

Diagnostic Imaging

Abdominal Ultrasonography:

• ·The liver appears diffusely hyperechoic (brighter than normal) compared to the falciform fat and the right renal cortex, a hallmark finding attributed to increased lipid content within hepatocytes [6][1]
• ·Hepatomegaly is commonly appreciated [5]
• ·Ultrasound also allows evaluation for concurrent diseases such as pancreatitis, biliary disease, or neoplasia [4][6]
• ·However, ultrasonography alone cannot distinguish FHL from other causes of hepatic hyperechogenicity, such as steroid hepatopathy or vacuolar hepatopathy [6]

Cytology and Histopathology

• ·Fine-needle aspirate (FNA) cytology: Considered highly diagnostic and minimally invasive; aspirates reveal hepatocytes with large, clear cytoplasmic lipid vacuoles displacing the nucleus peripherally [1][3]
• ·Liver biopsy (histopathology): Definitive diagnosis; reveals diffuse macrovesicular and microvesicular hepatic steatosis affecting more than 50% of hepatocytes [1][5]. Biopsy also allows concurrent hepatic diseases (e.g., cholangiohepatitis, lymphoma) to be identified or excluded [3]
• ·Coagulation status should be assessed before any invasive sampling due to risk of hemorrhage [1]

The cornerstone of FHL treatment is aggressive nutritional support combined with correction of underlying metabolic abnormalities and management of any concurrent disease [1][3][5]. The fundamental goal is to supply sufficient caloric and protein intake to reverse peripheral fat mobilization and restore hepatic metabolic function.

Enteral Nutritional Support

Voluntary food intake is almost universally inadequate in affected cats, necessitating assisted feeding [3][5]. Forced syringe-feeding is generally inadequate and may provoke food aversion; therefore, placement of a feeding tube is strongly recommended [5]:

• ·Nasogastric/nasoesophageal (NG/NE) tube: Useful for short-term use (days) while awaiting recovery or surgical preparation; well-tolerated but limits the viscosity of food that can be delivered [5]
• ·Esophagostomy tube (E-tube): The preferred method for most FHL patients; allows delivery of blended complete diets, can be maintained for weeks to months, and is well-tolerated by most cats [1][3][5]
• ·Percutaneous endoscopic gastrostomy (PEG) tube or jejunostomy tube: Reserved for cats in which esophageal access is contraindicated [5]

Caloric targets typically begin at approximately 25–30% of resting energy requirement (RER) on day 1, gradually increasing over 5–7 days to full RER to minimize the risk of refeeding syndrome [1][5]. RER is calculated as 70 × (body weight in kg)^0.75.

A high-protein, high-calorie diet is essential; protein restriction should be avoided unless overt hepatic encephalopathy is present [1][5]. Commercially available feline critical care diets (e.g., Hill's a/d, Royal Canin Recovery) are commonly used.

Fluid Therapy and Electrolyte Correction

• ·Intravenous or subcutaneous fluid therapy is used to correct dehydration; Lactated Ringer's solution or Plasma-Lyte A is preferred over 0.9% NaCl to avoid hyperchloremic acidosis [1][5]
• ·Potassium supplementation: Hypokalemia is common and worsens with refeeding; potassium chloride supplementation in fluids is routinely provided and monitored closely [1][5]
• ·Phosphorus supplementation: Hypophosphatemia post-refeeding can cause hemolytic anemia and muscle weakness; phosphorus levels should be monitored daily during the initial refeeding period [1][5]
• ·Dextrose-containing fluids should be used cautiously or avoided to prevent worsening hyperglycemia or exacerbating thiamine depletion [5]

Pharmacological Support

• ·Vitamin B12 (cobalamin): Frequently deficient in cats with hepatic disease and concurrent gastrointestinal involvement; parenteral supplementation is recommended [4][5]
• ·Vitamin K1: Administered subcutaneously or intramuscularly in cats with suspected coagulopathy or prior to invasive procedures; essential for hepatic synthesis of clotting factors [1][5]
• ·Vitamin E and other antioxidants: Vitamin E (alpha-tocopherol) and S-adenosylmethionine (SAMe) may be used to reduce oxidative hepatocellular injury [5]
• ·L-carnitine: Supplementation may support mitochondrial fatty acid oxidation; evidence is primarily extrapolated from the proposed pathophysiological role of carnitine deficiency [2][8]
• ·Thiamine (Vitamin B1): Supplementation is recommended, particularly in cats with neurological signs, given the risk of deficiency with prolonged anorexia [5]
• ·Antiemetics: Maropitant (Cerenia) or ondansetron are used to control nausea and vomiting and to facilitate tolerance of tube feeding [3]
• ·Hepatoprotectants: SAMe and milk thistle (silymarin) are commonly employed to support hepatocyte regeneration and reduce oxidative stress [5]
• ·Appetite stimulants: Mirtazapine may be used adjunctively to encourage voluntary intake; however, forced tube feeding remains more reliable in acute illness [3]

Management of Concurrent Disease

It is critical to identify and treat any underlying condition (e.g., pancreatitis, cholangitis, neoplasia, diabetes mellitus, urinary obstruction) simultaneously, as failure to address the primary cause will result in relapse or treatment failure [3][4].

The prognosis for FHL is highly dependent on the speed of diagnosis, the presence or absence of an underlying concurrent disease, and the aggressiveness of nutritional support [3][5].

Survival rates with aggressive treatment are favorable:

• ·With prompt diagnosis and appropriate enteral nutritional support, survival rates of approximately 60–90% have been reported in the literature [5][3]
• ·Center (2005) emphasized that early recognition and intervention—sometimes as simple as ensuring adequate intake of a complete balanced diet in cats in the earliest stages—can be life-saving [5]
• ·Webb (2018) underscored that if recognized early and treated appropriately, the prognosis is good; however, if FHL is not recognized or treatment is delayed or inadequate, the prognosis is grave [3]

Prognostic factors:

• ·Idiopathic FHL generally carries a better prognosis than secondary FHL, as the underlying cause in the latter may independently worsen the outcome [3][8]
• ·Concurrent severe diseases such as pancreatitis with systemic complications, neoplasia, or advanced renal failure significantly worsen prognosis [4][3]
• ·The degree of hepatic dysfunction at presentation (severity of hyperbilirubinemia, degree of coagulopathy, presence of hepatic encephalopathy) correlates with prognosis [1][5]
• ·Cats that develop severe hypophosphatemia-induced hemolytic anemia, refractory hepatic encephalopathy, or profound coagulopathy have a guarded to poor prognosis [1][5]
• ·Once a cat begins eating voluntarily and bilirubin levels decline, recovery is typically progressive and may take several weeks to months for complete hepatic lipid clearance [5]

Long-term outlook:

• ·Cats that recover fully from an episode of FHL can return to a normal quality of life with no permanent hepatic impairment, provided the underlying cause is controlled [5][3]
• ·Without treatment, FHL is invariably fatal [3]

Although FHL cannot always be entirely prevented, several management strategies can significantly reduce its incidence and mitigate risk:

• ·Maintain healthy body weight: Preventing obesity is the single most important preventive measure, as obese cats are at substantially greater risk due to their larger peripheral fat stores available for mobilization [1][5]
• ·Avoid sudden or prolonged food deprivation: Owners should monitor daily food intake and seek veterinary attention promptly if a cat refuses food for more than 24–48 hours, particularly in obese cats [3][5]
• ·Gradual dietary transitions: When changing a cat's diet, do so incrementally over 7–14 days to prevent voluntary food refusal and associated anorexia [3]
• ·Stress reduction: Minimize environmental stressors (rehoming, introduction of new pets, changes in routine) and use pheromone diffusers (e.g., Feliway) to reduce stress-induced anorexia [3][5]
• ·Regular veterinary monitoring: Routine wellness examinations allow for early detection of underlying diseases (e.g., diabetes mellitus, renal disease, hyperthyroidism) that may predispose cats to anorexia and secondary FHL [3]
• ·Nutritional management during illness: Cats admitted to hospital for any reason should have their nutritional intake carefully monitored; early nutritional intervention (appetite stimulants, assisted feeding) should be initiated if voluntary intake is inadequate for more than 3 days [1][3]
• ·No vaccine exists for FHL, as it is a metabolic disorder rather than an infectious disease